Cpwm LLC trimmed its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 55.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,460 shares of the biopharmaceutical company’s stock after selling 9,218 shares during the period. Cpwm LLC’s holdings in Bristol-Myers Squibb were worth $463,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of BMY. Alps Advisors Inc. bought a new stake in Bristol-Myers Squibb in the second quarter valued at $529,000. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Bristol-Myers Squibb by 3,096.0% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,762 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 4,613 shares during the period. Factorial Partners LLC acquired a new position in shares of Bristol-Myers Squibb during the second quarter valued at $3,071,000. Capital Investment Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb by 41.7% during the second quarter. Capital Investment Advisory Services LLC now owns 5,608 shares of the biopharmaceutical company’s stock valued at $310,000 after purchasing an additional 1,650 shares during the period. Finally, Integrated Investment Consultants LLC increased its holdings in shares of Bristol-Myers Squibb by 1,748.8% during the second quarter. Integrated Investment Consultants LLC now owns 63,468 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 60,035 shares during the period. Institutional investors and hedge funds own 72.74% of the company’s stock.
A number of research analysts have recently commented on the company. Societe Generale set a $47.00 price target on Bristol-Myers Squibb and gave the company a “sell” rating in a report on Wednesday, November 14th. BMO Capital Markets raised their price target on Bristol-Myers Squibb from $55.00 to $58.00 and gave the company a “market perform” rating in a report on Friday, November 16th. William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a report on Tuesday, November 27th. Morgan Stanley lowered their price target on Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday, November 6th. Finally, Credit Suisse Group set a $61.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Sunday, October 14th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $61.95.
NYSE:BMY opened at $53.25 on Friday. The stock has a market cap of $84.92 billion, a P/E ratio of 17.69, a PEG ratio of 1.45 and a beta of 1.11. Bristol-Myers Squibb Co has a 52-week low of $46.94 and a 52-week high of $70.05. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.18. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. Sell-side analysts anticipate that Bristol-Myers Squibb Co will post 3.87 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, February 1st. Investors of record on Friday, January 4th will be issued a dividend of $0.41 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. This represents a $1.64 dividend on an annualized basis and a yield of 3.08%. Bristol-Myers Squibb’s payout ratio is presently 53.16%.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://transcriptdaily.com/2018/12/07/cpwm-llc-has-463000-holdings-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.